CORDIS
EU research results

CORDIS

English EN

Living autologous heart valves for minimally invasive implantable procedures

Objective

Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease with almost 200.000 annual implantations worldwide. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. A particularly severe problem relates to children with congenital heart defects (1% of all newborns) who cannot be treated efficiently due to the lack of growths of the clinically available “artificial” valve prostheses. The principal objective of the LifeValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. Two novel life science technologies will be combined: tissue engineering and minimally invasive implantation technology. In particular, the scientific and technological approach of the LifeValve project is to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growths which can be implanted by minimally invasive catheter technology. First clinical trials will be enrolled in paediatric patients addressing the currently unmet dramatic medical need for growing implants. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. In addition, close industry-academia collaborations are integrated. It is expected that new knowledge applicable for a much broader field of cardiovascular diseases will be generated by the unique combination of consortium partners each representing opinion leaders in their fields. The consortium is compact comprising all the necessary expertise and skills to realize the precisely planned work in a short period of time.The close collaboration of the well interconnected LifeValve consortium will most efficiently contribute to an added value for the EU.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAT ZURICH

Address

Ramistrasse 71
8006 ZÜRich

Switzerland

Activity type

Other

EU Contribution

€ 2 470 000

Administrative Contact

Simon Philipp Hoerstrup (Prof.)

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

DEUTSCHES HERZZENTRUM BERLIN

Germany

EU Contribution

€ 3 142 372

TECHNISCHE UNIVERSITEIT EINDHOVEN

Netherlands

EU Contribution

€ 1 784 000

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 215 480

pfm Produkte fur die Medizin AG

Germany

EU Contribution

€ 201 000

XELTIS AG

Switzerland

EU Contribution

€ 850 500

XELTIS BV

Netherlands

EU Contribution

€ 1 146 000

DEBRECENI EGYETEM

Hungary

EU Contribution

€ 67 000

Project information

Grant agreement ID: 242008

Status

Closed project

  • Start date

    1 November 2009

  • End date

    30 April 2015

Funded under:

FP7-HEALTH

  • Overall budget:

    € 16 062 828,60

  • EU contribution

    € 9 876 352

Coordinated by:

UNIVERSITAT ZURICH

Switzerland